Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research Article
  • Published:

Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia

Molecular Psychiatry volume 7, pages 695–705 (2002)Cite this article

Abstract

Extrapyramidal adverse symptoms (EPS) represent a major type of adverse events in treatment with typical antipsychotic drugs which share high affinity to the dopamine D2 receptor (DRD2). Genetic variants of this receptor may modulate the therapeutic response and the severity of adverse symptoms of antipsychotics. We analyzed nine known polymorphisms of the DRD2 in 665 schizophrenic patients with European Caucasian ethnic background and compared the intensity of acute dystonia, extrapyramidal symptoms, akathisia, and tardive dyskinesia between carriers of different DRD2 genotypes. In a subgroup of 40 patients with most severe extrapyramidal symptoms we sequenced the coding region including the exon-intron junctions of the DRD2 gene. Functionally relevant DRD2 amino acid variants (Ser310, Cys311) were rare or were not found at all (Ala96). Complete sequence analysis of sufferers from the most severe adverse effects revealed two new intronic polymorphisms and a silent polymorphism in exon 7, but no new amino acid variants beyond those which are already known. We found no significant association between these polymorphisms and the intensity of the different types of adverse neurologic effects of the antipsychotics. These results were obtained by correlating adverse events with each of the nine single nucleotide polymorphisms and by correlation with the estimated haplotypes. In conclusion, genetic variations in the DRD2 gene were no major predictors of the individually variable adverse effects from antipsychotic treatment in Caucasian schizophrenic patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Grohmann R, Koch R, Schmidt LG . Extrapyramidal symptoms in neuroleptic recipients Agents Actions Suppl 1990; 29: 71–82

    Article  CAS  Google Scholar 

  2. Jaber M, Robinson SW, Missale C, Caron MG . Dopamine receptors and brain function Neuropharmacology 1996; 35: 1503–1519

    Article  CAS  Google Scholar 

  3. Hardie RJ, Lees AJ . Neuroleptic induced Parkinson's syndrome: clinical features and results of treatment with levodopa J Neurol Neurosurg Psychiatry 1988; 51: 850–854

    Article  CAS  Google Scholar 

  4. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P . Reversible drug-induced parkinsonism: clinicopathologic study of two cases Arch Neurol 1982; 39: 644–646

    Article  CAS  Google Scholar 

  5. Sakalis G, Curry SH, Mould GP, Lader MH . Physiologic and clinical effects of chlorpromazine and their relationship to plasma level Clin Pharmacol Therapeut 1972; 13: 931–946

    Article  CAS  Google Scholar 

  6. Cohen G, Spina MB . Deprenyl suppresses the oxidant stress associated with increased dopamine turnover Annal Neurol 1989; 26: 689–690

    Article  CAS  Google Scholar 

  7. Scatton B, Garrett C, Julow L . Acute and subacute effects of neuroleptics on dopamine synthesis and release in the rat striatum Arch Pharmacol 1975; 289: 419–434

    Article  CAS  Google Scholar 

  8. Farde L . Selective D1 and D2-dopamine receptor blockade both induces akathisia in humans: a PET study with (11C)SCH 23390 and (11C)raclopride Psychopharmacology 1992; 107: 23–29

    Article  CAS  Google Scholar 

  9. Farde L, Nordström A, Wiesel FA, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine Arch Gen Psychiatry 1992; 49: 539–544

    Article  Google Scholar 

  10. Sachdev PS, Saharov T . Effects of specific dopamine D1 and D2 receptor antagonists and agonist and neuroleptic drugs on emotional defecation in a rat model of akathisia Psychiatry Res 1998; 81: 323–332

    Article  CAS  Google Scholar 

  11. Egan MF, Hurd Y, Hyde TM, Weinberger DR, Wyatt RJ, Kleinman JE . Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias Synapse 1994; 18: 178–189

    Article  CAS  Google Scholar 

  12. Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP . Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies J Psychiatry Res 1998; 32: 201–214

    Article  CAS  Google Scholar 

  13. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L et al. Cloning of the cDNA and gene for a human D2 dopamine receptor Proc Natl Acad Sci USA 1989; 86: 9762–9766

    Article  CAS  Google Scholar 

  14. Gandelman KY, Harmon S, Todd RD, O'Malley KL . Analysis of the structure and expression of the human dopamine D2A receptor gene J Neurochem 1991; 56: 1024–1029

    Article  CAS  Google Scholar 

  15. Brockmöller J, Kaiser R . Receptor polymorphisms and psychotropic drug response In: Balant LP, Benitez J, Dahl LF, Pinder RM, Potter WZ (eds) European Cooperation in the Field of Scientific and Technical Research. Clinical Pharmacology in Psychiatry: Finding the Right Dose of Psychotropic Drugs European Commission: Brussels 1998; pp 203–232

    Google Scholar 

  16. Seemann P . Dopamine receptors. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology Raven Press: New York 1995; 295–302

    Google Scholar 

  17. Jönsson EG, Nöthen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers Mol Psychiatry 1999; 4: 290–296

    Article  Google Scholar 

  18. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers Mol Psychiatry 1998; 3: 256–260

    Article  CAS  Google Scholar 

  19. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK et al. D2 dopamine receptor gene (DRD2) TaqI A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele Pharmacogenetics 1997; 7: 479–484

    Article  CAS  Google Scholar 

  20. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients Pharmacogenetics 2000; 10: 335–341

    Article  CAS  Google Scholar 

  21. Cravchik A, Sibley DR, Gejman PV . Functional analysis of the human D2 dopamine receptor missense variants J Biol Chem 1996; 271: 26013–26017

    Article  CAS  Google Scholar 

  22. Cravchik A, Sibley DR, Gejman PV . Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants Pharmacogenetics 1999; 9: 17–23

    Article  CAS  Google Scholar 

  23. Simpson GM, Angus JW . A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 1970; 212: 11–19

    Article  CAS  Google Scholar 

  24. Barnes TR . A rating scale for drug-induced akathisia Br J Psychiatry 1989; 154: 672–676

    Article  CAS  Google Scholar 

  25. Smith JM, Kucharski LT, Oswald WT, Waterman LJ . A systematic investigation of tardive dyskinesia in inpatients Am J Psychiatry 1979; 136: 918–922

    Article  CAS  Google Scholar 

  26. Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 1982; 39: 486–487

    CAS  Google Scholar 

  27. Arinami T, Gao M, Hamaguchi H, Toru M . A functional polymorphism in the promotor region of the dopamine D2 receptor gene is associated with schizophrenia Hum Mol Genetics 1997; 6: 577–582

    Article  CAS  Google Scholar 

  28. Grandy DK, Zhang Y, Civelli O . PCR detection of the TaqA RFLP at the DRD2 locus Hum Mol Genet 1993; 57: 1445

    Google Scholar 

  29. Castiglione CM, Deinard AS, Speed WC, Sirugo G, Rosenbaum HC, Zhang Y et al. Evolution of haplotypes at the DRD2 locus Am J Hum Genet 1995; 57: 1445–1456

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Kidd K, Pakstis J, Castiglione CM, Kidd JR, Speed C, Goldman D et al. DRD2 haplotypes containing the Taq IA1 allele: Implications for alcoholism research Alcohol Clin Exp Res 1996; 20: 697–705

    Article  CAS  Google Scholar 

  31. Higuchi S, Muramatsu T, Murayama M, Hayashida M . Association of structural polymorphism of the dopamine D2 receptor gene and alcoholism Biochem Biophysic Res Comm 1994; 204: 1199–1205

    Article  CAS  Google Scholar 

  32. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H et al. Association of dopamine D2 receptor molecular variant with schizophrenia Lancet 1994; 343: 703–704

    Article  CAS  Google Scholar 

  33. Terwilliger JD, Ott J . Handbook of Human Genetic Linkage The Johns Hopkins University Press: Baltimore 1994

    Google Scholar 

  34. Blaisdell GD . Akathisia: a comprehensive review and treatment summary Pharmacopsychiatry 1994; 27: 139–146

    Article  CAS  Google Scholar 

  35. Ebadi M, Srinivasan SK . Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders Pharmacol Rev 1995; 47: 575–604

    CAS  PubMed  Google Scholar 

  36. Kane JM . Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics Psychopharmacol Bull 1992; 28: 227–229

    CAS  PubMed  Google Scholar 

  37. Laruelle M, Gelernter J, Innis R . D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene Mol Psychiatry 1998; 3: 261–265

    Article  CAS  Google Scholar 

  38. Mihara K, Suzuki A, Kondo T, Nagashima U, Ono S, Otani K et al. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study Am J Med Genet 2000; 96: 422–424

    Article  CAS  Google Scholar 

  39. Chen CH, Wei FC, Koong FJ, Hsiao KJ . Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia Biol Psychiatry 1997; 41: 827–829

    Article  CAS  Google Scholar 

  40. Jönsson EG, Nöthen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M et al. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia Schizophr Res 1999; 40: 31–36

    Article  Google Scholar 

  41. Breen G, Brown J, Maude S, Fox H, Collier D, Li T et al. −141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population Am J Med Genet 1999; 88: 407–410

    Article  CAS  Google Scholar 

  42. Stöber G, Jatzke S, Heils A, Jungkunz G, Knapp M, Mossner R et al. Insertion/deletion variant (−141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder J Neural Transm 1998; 105: 101–109

    Article  Google Scholar 

  43. Tallerico T, Ulpian C, Liu I . Dopamine D2 receptor promoter polymorphism: no association with schizophrenia Psychiatry Res 1999; 85: 215–219

    Article  CAS  Google Scholar 

  44. Pohjalainen T, Nagren K, Syvalahti EK, Hietala J . The dopamine D2 receptor 5′-flanking variant, −141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo Pharmacogenetics 1999; 9: 505–509

    CAS  PubMed  Google Scholar 

  45. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K . Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia Psychiatry Res 1998; 16: 117–123

    Article  Google Scholar 

  46. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D et al. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis JAMA 1994; 271: 204–208

    Article  CAS  Google Scholar 

  47. Nanko S, Hattori M, Dai XY, Fukuda R, Kazamatsuri H . DRD2 Ser311/Cys311 polymorphism in schizophrenia Lancet 1994; 343: 1044

    Article  CAS  Google Scholar 

  48. Hattori M, Nanko S, Dai XY, Fukuda R, Kazamatsuri H . Mismatch PCR RFLP detection of DRD2 Ser311Cys polymorphism and schizophrenia Biochem Biophys Res Commun 1994; 202: 757–763

    Article  CAS  Google Scholar 

  49. Chen CH, Chien SH, Hwu HG . No association of dopamine D2 receptor molecular variant Cys311 and schizophrenia in Chinese patients Am J Med Genet 1996; 67: 418–420

    Article  CAS  Google Scholar 

  50. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M . A structural polymorphism of human dopamine D2 receptor, D2(Ser311-->Cys) Biochem Biophys Res Commun 1993; 196: 1369–1375

    Article  CAS  Google Scholar 

  51. Tanaka T, Igarashi S, Onodera O, Tanaka H, Fukushima N, Takahashi M et al. Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia Am J Med Genet 1996; 67: 208–211

    Article  CAS  Google Scholar 

  52. Spurlock G, Williams J, McGuffin P, Aschauer HN, Lenzinger E, Fuchs K et al. European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms Am J Med Genet 1998; 81: 24–28

    Article  CAS  Google Scholar 

  53. Sasaki T, Macciardi FM, Badri F, Verga M, Meltzer HY, Lieberman J et al. No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis Am J Med Genet 1996; 67: 415–417

    Article  CAS  Google Scholar 

  54. Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R . DRD2 Ser311/Cys311 polymorphism in schizophrenia Lancet 1994; 343: 1045–1046

    CAS  PubMed  Google Scholar 

  55. Nöthen MM, Wildenauer D, Cichon S, Albus M, Maier W, Minges J et al. Dopamine D2 receptor molecular variant and schizophrenia Lancet 1994; 343: 1301–1302

    Article  Google Scholar 

  56. Laurent C, Bodeau-Pean S, Campion D, D'Amato T, Jay M, Dollfus S et al. No major role for the dopamine D2 receptor Ser-->Cys311 mutation in schizophrenia Psychiatr Genet 1994; 4: 229–230

    Article  CAS  Google Scholar 

  57. Crawford F, Hoyne J, Cai X, Osborne A, Poston D, Zaglul J et al. Dopamine DRD2/Cys311 is not associated with chronic schizophrenia Am J Med Genet 1996; 67: 483–484

    Article  CAS  Google Scholar 

  58. Asherson P, Williams N, Roberts E, McGuffin M, Owen M . DRD2 Ser311/Cys311 polymorphism in schizophrenia Lancet 1994; 343: 1045

    CAS  PubMed  Google Scholar 

  59. Verga M, Macciardi F, Pedrini S, Cohen S, Smeraldi E . No association of the Ser/Cys311 DRD2 molecular variant with schizophrenia using a classical case control study and the haplotype relative risk Schizophr Res 1997; 25: 117–121

    Article  CAS  Google Scholar 

  60. Arinami T, Itokawa M, Aoki J, Shibuya H, Ookubo Y, Iwawaki A et al. Further association study on dopamine D2 receptor variant S311C in schizophrenia and affective disorders Am J Med Genet 1996; 67: 133–138

    Article  CAS  Google Scholar 

  61. Kaneshima M, Higa T, Nakamoto H, Nagamine M . An association study between the Cys311 variant of dopamine D2 receptor gene and schizophrenia in the Okinawan population Psychiatry Clin Neurosci 1997; 51: 379–381

    Article  CAS  Google Scholar 

  62. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia Neuropsychopharmacology 1999; 21: 17–27

    Article  CAS  Google Scholar 

  63. Lovlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM . Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients Int J Neuropsychopharmacol 2000; 3: 61–65

    Article  CAS  Google Scholar 

  64. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ . Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients Neuropsychobiology 2001; 44: 95–98

    Article  CAS  Google Scholar 

  65. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 1999; 4: 247–253

    Article  CAS  Google Scholar 

  66. Steen VM, Lovlie R, MacEwan T, McCreadie RG . Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Mol Psychiatry 1997; 2: 139–145

    Article  CAS  Google Scholar 

  67. Rietschel M, Nöthen MM, Albus M, Maier W, Minges J, Bondy B et al. Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases Schizophr Res 1996; 20: 181–186

    Article  CAS  Google Scholar 

  68. Garcia-Barcelo MM, Lam LC, Ungvari GS, Lam VK, Tang WK . Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients J Neural Transm 2001; 108: 671–677

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the German Ministry for Education and Research (BMBF), grants 01EC9408 and 01ZZ9511. We thank Prof Dr R Uebelhack, Prof Dr B Nickel and Dr A Mackert for constant support of this study in their departments. Furthermore, we thank Dr D Filler, S Brockmeier, G Rott, S Strobel, M Lange, S Trautner, K Maronde, O Lüers, O Bartz, M Stiller, M Kaiser and L Reinfried for their contributions to the work. We also thank M Maszynski and A Alfandega for their technical assistance.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Universitätsklinikum Charité, Humboldt Universität zu Berlin, Berlin, Germany

    R Kaiser, P-B Tremblay, F Klufmöller, I Roots & J Brockmöller

  2. Institute of Clinical Pharmacology, Universitätsklinikum der Georg-August-Universität Göttingen, Göttingen, Germany

    R Kaiser & J Brockmöller

Authors
  1. R Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P-B Tremblay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Klufmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Roots
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Brockmöller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaiser, R., Tremblay, PB., Klufmöller, F. et al. Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7, 695–705 (2002). https://doi.org/10.1038/sj.mp.4001054

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001054

Keywords

This article is cited by

Search

Advanced search

Quick links